Sagene Pharmaceuticals is a biopharmaceutical company developing novel applications for combinations of FDA-approved drugs to treat diseases associated with aging. Sagene has shown that selective MAO-B inhibitors, specifically selegiline (l-deprenyl), can reduce side effects and enhance efficacy in combination with current treatments for erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases by targeting multiple disease pathways not typically addressed by currently approved drugs.

Learn more about Sagene

Sagene is targeting for erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation and cardiovascular diseases. These indications represent large markets for which current treatments have serious side effects or limitations.

Learn more about our pipeline